[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1383734T3 - Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater - Google Patents

Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater

Info

Publication number
DK1383734T3
DK1383734T3 DK02722569T DK02722569T DK1383734T3 DK 1383734 T3 DK1383734 T3 DK 1383734T3 DK 02722569 T DK02722569 T DK 02722569T DK 02722569 T DK02722569 T DK 02722569T DK 1383734 T3 DK1383734 T3 DK 1383734T3
Authority
DK
Denmark
Prior art keywords
intermediates
compounds useful
aminoquinoline derivatives
aminoquinoline
derivatives
Prior art date
Application number
DK02722569T
Other languages
English (en)
Inventor
David B Damon
Robert DUGGER
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1383734T3 publication Critical patent/DK1383734T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK02722569T 2001-04-30 2002-04-08 Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater DK1383734T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
DK1383734T3 true DK1383734T3 (da) 2006-05-15

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02722567T DK1425270T3 (da) 2001-04-30 2002-04-08 Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer
DK02722569T DK1383734T3 (da) 2001-04-30 2002-04-08 Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02722567T DK1425270T3 (da) 2001-04-30 2002-04-08 Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer

Country Status (25)

Country Link
US (3) US6600045B2 (da)
EP (2) EP1383734B1 (da)
JP (2) JP3924251B2 (da)
KR (2) KR100639745B1 (da)
CN (3) CN100357265C (da)
AR (3) AR035963A1 (da)
AT (2) ATE316957T1 (da)
AU (1) AU2002253448B2 (da)
BR (2) BR0209238A (da)
CA (2) CA2445693A1 (da)
CZ (2) CZ20032900A3 (da)
DE (2) DE60210265T2 (da)
DK (2) DK1425270T3 (da)
ES (2) ES2259080T3 (da)
HK (1) HK1062294A1 (da)
HU (2) HUP0304039A3 (da)
IL (2) IL157544A0 (da)
MX (2) MXPA03009935A (da)
PL (2) PL366700A1 (da)
PT (1) PT1425270E (da)
RU (2) RU2259355C2 (da)
TW (1) TWI250974B (da)
WO (2) WO2002088069A2 (da)
YU (2) YU84303A (da)
ZA (2) ZA200306599B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
MXPA05009331A (es) * 2003-03-17 2005-11-04 Kaneka Corp Metodo para producir un derivado de amida del acido (r)-3-[4-(trifluorometil)fenilamino]-pentanoico.
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
NZ569469A (en) 2003-09-26 2010-03-26 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
US7749992B2 (en) * 2003-10-08 2010-07-06 Eli Lilly And Company Compounds and methods for treating dislipidemia
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
EP1740547A1 (en) * 2004-04-07 2007-01-10 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006012093A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
EP1861372A1 (en) 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1896402A4 (en) * 2005-06-20 2010-07-28 Astrazeneca Ab PROCESS FOR THE SYNTHESIS OF (ALKOXYCARBONYLAMINO) ALKYLSULFONATES
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
KR101442644B1 (ko) 2011-04-12 2014-09-19 주식회사 종근당 Ｃｅｔｐ 억제제로서의 사이클로알케닐 아릴 유도체
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CA2891710C (en) 2013-01-31 2017-08-01 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105706289A (zh) * 2013-11-11 2016-06-22 隆萨有限公司 利用路易斯酸制备第13族元素的氰基化合物的方法
CN107108558B (zh) * 2014-08-12 2019-11-19 狄智玛制药私人有限公司 制备用于制备四氢喹啉衍生物的合成中间体的方法
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360634T1 (de) 1998-07-10 2007-05-15 Massachusetts Inst Technology Ligande für metalle und verbesserte metall- katalysierte verfahren, die darauf basieren
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
CN100357265C (zh) 2007-12-26
CN1267411C (zh) 2006-08-02
US20030073843A1 (en) 2003-04-17
AR035963A1 (es) 2004-07-28
CZ20032900A3 (cs) 2004-06-16
US6689897B2 (en) 2004-02-10
PT1425270E (pt) 2006-07-31
AU2002253448B2 (en) 2007-07-05
KR20040015200A (ko) 2004-02-18
MXPA03009935A (es) 2004-01-29
ATE316957T1 (de) 2006-02-15
ZA200306600B (en) 2004-08-25
CZ20032898A3 (cs) 2004-07-14
CN1297541C (zh) 2007-01-31
YU84403A (sh) 2006-08-17
MXPA03009936A (es) 2004-01-29
PL366584A1 (en) 2005-02-07
EP1383734B1 (en) 2006-02-01
JP3924250B2 (ja) 2007-06-06
EP1425270B1 (en) 2006-03-29
CA2445623A1 (en) 2002-11-07
HUP0304039A2 (hu) 2004-03-29
DE60209004T2 (de) 2006-09-28
ATE321755T1 (de) 2006-04-15
WO2002088069A9 (en) 2003-12-04
TWI250974B (en) 2006-03-11
WO2002088085A3 (en) 2004-03-25
HUP0304039A3 (en) 2005-10-28
KR100591998B1 (ko) 2006-06-22
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
US20020177716A1 (en) 2002-11-28
PL366700A1 (en) 2005-02-07
WO2002088069A2 (en) 2002-11-07
CN1505609A (zh) 2004-06-16
RU2265010C2 (ru) 2005-11-27
US6600045B2 (en) 2003-07-29
WO2002088085A2 (en) 2002-11-07
DE60210265T2 (de) 2006-10-12
JP3924251B2 (ja) 2007-06-06
CN1680292A (zh) 2005-10-12
BR0209291A (pt) 2004-07-13
IL157546A0 (en) 2004-03-28
HK1062294A1 (en) 2004-10-29
JP2004531541A (ja) 2004-10-14
US20030216576A1 (en) 2003-11-20
ZA200306599B (en) 2004-10-22
RU2003131870A (ru) 2005-01-27
DE60210265D1 (de) 2006-05-18
AR044706A2 (es) 2005-09-21
ES2256461T3 (es) 2006-07-16
RU2003131871A (ru) 2005-04-10
WO2002088069A3 (en) 2003-02-20
HUP0304041A2 (hu) 2004-04-28
DK1425270T3 (da) 2006-07-03
EP1383734A2 (en) 2004-01-28
KR100639745B1 (ko) 2006-10-30
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
JP2004527556A (ja) 2004-09-09
DE60209004D1 (de) 2006-04-13
EP1425270A2 (en) 2004-06-09
CA2445693A1 (en) 2002-11-07
YU84303A (sh) 2006-05-25
US6706881B2 (en) 2004-03-16
IL157544A0 (en) 2004-03-28
HUP0304041A3 (en) 2005-08-29
HU225777B1 (en) 2007-08-28
ES2259080T3 (es) 2006-09-16
CN1529696A (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
DK1383734T3 (da) Forbindelser, der er anvendelige som mellemprodukter til 4-aminoquinolinderivater
DK1491540T3 (da) Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
DK1386921T3 (da) Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
DK1436271T6 (da) Phenylpiperazinderivater som serotonin-genoptagelseshæmmere
LTC1480644I2 (lt) Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
DK1171443T3 (da) Bicykliske, heteroaromatiske forbindelser, der er nyttige som LH-agonister
NO20035193D0 (no) Nye pyrrolderivater som farmasöytiske midler
NO20033683L (no) 2,4-disubstituerte pyrimidin-5-karboksamidderivater som KCNQ kaliumkanal modulatorer
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
IS6971A (is) Ný efnasambönd
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
DK1404667T3 (da) Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1501787T3 (da) N-biphenylmethylaminocycloalkancarboxamid-derivater med en substituerent på methyl, der er nyttige som bradykininantagonister
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
WO2005087700A3 (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
DK1651640T3 (da) Nicotinamid derivater, der er anvendelige som PDE4 inhibitorer
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1390351T3 (da) Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer
NO20060603L (no) Fremgangsmate for fremstillingen av fenyltetrazolderivater